The Price Is Not Right: AstraZeneca Puts Nexium On Sale
This article was originally published in The Pink Sheet Daily
Executive Summary
Marketing shift will target branded proton pump inhibitors for market share gains rather than generic Prilosec.
You may also be interested in...
Nexium Is Part Of Anti-Competitive Plan To Thwart Generic Prilosec, Retailer Suit Against AstraZeneca Says
Walgreen’s, Eckerd and Kroger are among the retailers filing suit against AstraZeneca over the launch of the Prilosec follow-on Nexium.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: